Document Detail


Management of life-threatening hemorrhages and unsafe interventions in nonhemophiliac children by recombinant factor VIIa.
MedLine Citation:
PMID:  18838398     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The literature on the use of recombinant factor VIIa (rFVIIa), which was initially used in hemophiliac patients with inhibitors, for hemorrhages that cannot be managed with conventional methods or operations that cannot be performed safely is increasingly growing. This study presents a group of nonhemophiliac patients with hemorrhagic problems or hemorrhage risk for some interventions that were successfully resolved with the use of rFVIIa. The patient group was composed of 20 patients with different disorders resulting in similar results as hemorrhage or hemorrhage risk. Most of the patients were diagnosed with liver disorders primary or secondary to other diseases. The remaining cases were patients with leukemia, sepsis, intracranial hemorrhage, and burn. Some of the patients had multiple problems like a patient with liver disorder and intracranial hemorrhage or a leukemia patient with sepsis and disseminated intravascular coagulation. rFVIIa had been administered to the patients at dosages between 70 and 150 microg/kg up to 6 doses with 2-hour to 3-hour intervals. All the patients had benefited from the use of rFVIIa even though some of them died because of primary disease. This study shows that rFVIIa can be safely used in high-risk patients with a history of recurrent hemorrhage, for whom no improvement can be achieved in the hemostasis tests.
Authors:
G?ksel Leblebisatan; Ilgen Sasmaz; Bulent Antmen; Dincer Yildizdas; Yurdanur Kilinc
Related Documents :
16999978 - Home anticoagulation testing: predictors of rural patient interest.
7565188 - Acquired haemophilia--a therapeutic challenge.
15232118 - Spinal dural arteriovenous fistulas are not associated with prothrombotic factors.
957998 - Covert anticoagulant ingestion: study of 25 patients and review of world literature.
3987058 - Cerebrospinal fluid beta-glucuronidase activities in patients with central nervous syst...
18840578 - Transportation of critically ill patients on extracorporeal membrane oxygenation.
Publication Detail:
Type:  Journal Article     Date:  2008-10-06
Journal Detail:
Title:  Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis     Volume:  16     ISSN:  1938-2723     ISO Abbreviation:  Clin. Appl. Thromb. Hemost.     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-01-22     Completed Date:  2010-03-30     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9508125     Medline TA:  Clin Appl Thromb Hemost     Country:  United States    
Other Details:
Languages:  eng     Pagination:  77-82     Citation Subset:  IM    
Affiliation:
Department of Pediatric Hematology, Cukurova University Medical Faculty, Adana, Turkey. gokselleb@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Adolescent
Burns / blood,  complications
Child
Child, Preschool
Coagulants / therapeutic use*
Critical Illness
Factor VIIa / therapeutic use*
Female
Hemorrhage / blood,  drug therapy*,  etiology*
Humans
Infant
Leukemia / blood,  complications*
Liver Diseases / blood,  complications
Male
Off-Label Use
Recombinant Proteins / therapeutic use
Retrospective Studies
Sepsis / blood,  complications
Treatment Outcome
Chemical
Reg. No./Substance:
0/Coagulants; 0/Recombinant Proteins; 0/recombinant FVIIa; EC 3.4.21.21/Factor VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The nephrotic syndrome: an unusual case of multiple embolic events.
Next Document:  Clinical prediction of postoperative seizure control: structural, functional findings and disease hi...